Clinical Trial Detail

NCT ID NCT03924895
Title Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

invasive bladder transitional cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.